title: Invasive mould infections in the ICU setting: complexities and solutions.
abstract: Infections caused by filamentous fungi represent a major burden in the ICU. Invasive aspergillosis is emerging in non-neutropenic individuals with predisposing conditions, e.g. corticosteroid treatment, chronic obstructive pulmonary disease, liver cirrhosis, solid organ cancer, HIV infection and transplantation. Diagnosis is challenging because the signs and symptoms are non-specific, and initiation of additional diagnostic examinations is often delayed because clinical suspicion is low. Isolation of an Aspergillus species from the respiratory tract in critically ill patients, and tests such as serum galactomannan, bronchoalveolar lavage 1-3-β-d-glucan and specific PCR should be interpreted with caution. ICU patients should start adequate antifungal therapy upon suspicion of invasive aspergillosis, without awaiting definitive proof. Voriconazole, and now isavuconazole, are the drugs of choice. Mucormycosis is a rare, but increasingly prevalent disease that occurs mainly in patients with uncontrolled diabetes mellitus, immunocompromised individuals or previously healthy patients with open wounds contaminated with Mucorales. A high proportion of cases are diagnosed in the ICU. Rapidly progressing necrotizing lesions in the rhino-sinusal area, the lungs or skin and soft tissues are the characteristic presentation. Confirmation of diagnosis is based on demonstration of tissue invasion by non-septate hyphae, and by new promising molecular techniques. Control of underlying predisposing conditions, rapid surgical resection and administration of liposomal amphotericin B are the main therapeutic actions, but new agents such as isavuconazole are a promising alternative. Patients with mucormycosis receive a substantial part of their care in ICUs and, despite advances in diagnosis and treatment, mortality remains very high.
authors.affiliation: Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Universidad Complutense of Madrid, and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
authors.forename: Emilio
authors.initials: E
authors.lastname: Bouza
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D001230:Aspergillus / Q000187:drug effects / Q000302:isolation & purification; D016638:Critical Illness; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D016867:Immunocompromised Host; D007362:Intensive Care Units; D000072742:Invasive Fungal Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D008172:Lung Diseases, Fungal / Q000175:diagnosis* / Q000382:microbiology; D008351:Mannans / Q000097:blood; D009089:Mucor / Q000187:drug effects / Q000302:isolation & purification; D009091:Mucormycosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D009570:Nitriles / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D011725:Pyridines / Q000627:therapeutic use; D012137:Respiratory System / Q000382:microbiology; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole / Q000627:therapeutic use; D047071:beta-Glucans / Q000097:blood
chemical_list: D000935:Antifungal Agents; D008351:Mannans; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; D047071:beta-Glucans; C012990:galactomannan; C508735:isavuconazole; C033363:beta-1,3-glucan; D065819:Voriconazole; D005690:Galactose